Copyright
©The Author(s) 2019.
World J Hepatol. Jul 27, 2019; 11(7): 586-595
Published online Jul 27, 2019. doi: 10.4254/wjh.v11.i7.586
Published online Jul 27, 2019. doi: 10.4254/wjh.v11.i7.586
Table 1 Drugs and toxins implicated in cases of acute liver failure managed at the Victorian Liver Transplant Unit from 2002-2017
Drug/Toxins | Cases of ALF | Waitlisted for ELT | ELT |
(n = 101) | (n = 21) | (n = 13) | |
Paracetamol | 84 | 11 | 3 |
Antibiotics | 4 | 2 | 2 |
Amoxicillin/clavulanate (2), clarithromycin, isoniazid | |||
Infliximab | 2 | 2 | 2 |
Illicit drugs | 4 | 1 | 1 |
LSD, injected buprenorphine, amphetamines, MDMA | |||
NSAIDs | 1 | 1 | 1 |
Amanita phalloides | 1 | 1 | 1 |
Herbal medicines | |||
Black cohosh herb, kava kava | 2 | 2 | 2 |
Other | |||
Moxonidine, fenofibrate, chlorambucil | 3 | 1 | 1 |
Table 2 Demographics and aetiology of acute liver failure managed at the Victorian Liver Transplant Unit in a historical cohort† compared to current series
1988-20011 (n = 80) | 2002-2017 (n = 169) | P value | |||
n | % | n | % | ||
Referral rate2, median [IQR] | 1.2 [0.6;1.6] | 1.6 [1.3;1.7] | 0.020 | ||
Age, yr, median [IQR] | 36 [27.0;48.0] | 40 [30.0;52.0] | 0.168 | ||
Gender | |||||
Male | 16 | 20.0 | 37 | 21.9 | |
Female | 64 | 80.0 | 132 | 78.1 | 0.733 |
Aetiology | |||||
Paracetamol | 29 | 36.3 | 84 | 49.7 | 0.046 |
Viral hepatitis | 11 | 13.8 | 26 | 15.3 | 0.734 |
Hepatitis B | 8 | 10.0 | 20 | 11.8 | 0.669 |
Hepatitis A | 3 | 3.8 | 4 | 2.4 | 0.538 |
Varicella zoster | 0 | 0.0 | 1 | 0.1 | 0.491 |
Herpes simplex | 0 | 0.0 | 1 | 0.1 | 0.491 |
Non-paracetamol drug/toxin | 5 | 6.3 | 17 | 10.1 | 0.323 |
Indeterminate | 27 | 33.8 | 21 | 12.4 | <0.001 |
Autoimmune hepatitis | 0 | 0.0 | 9 | 5.3 | 0.036 |
Other | 8 | 10.0 | 12 | 7.1 | 0.432 |
Waitlisted for transplantation | 35 | 43.8 | 59 | 33.5 | 0.179 |
Waitlist mortality | 9 | 25.7 | 8 | 13.6 | 0.139 |
Liver transplantation | 26 | 32.5 | 42 | 24.9 | 0.206 |
Transplant-free survival | 30 | 37.5 | 88 | 52.1 | 0.032 |
Overall hospital survival | 50 | 62.5 | 122 | 72.2 | 0.122 |
Table 3 Outcomes of acute liver failure managed at the Victorian Liver Transplant Unit in a historical cohort† compared to the current series
Aetiology | TFS (%) | OS (%) | ||||||||
1988-20011 | 2002-2017 | P value | 1988-20011 | 2002-2017 | P value | |||||
n | % | n | % | n | % | n | % | |||
Paracetamol | 20 | 69.0 | 62 | 73.8 | 0.614 | 21 | 72.4 | 65 | 77.4 | 0.589 |
Non-paracetamol | 10 | 19.6 | 26 | 30.6 | 0.160 | 29 | 56.9 | 57 | 67.1 | 0.230 |
Viral hepatitis | 2 | 18.2 | 10 | 38.4 | 0.228 | 5 | 45.5 | 18 | 69.2 | 0.173 |
HBV | 2 | 25.0 | 7 | 35.0 | 0.609 | 4 | 50.0 | 14 | 70.0 | 0.318 |
HAV | 0 | 0.0 | 3 | 75.0 | 0.047 | 1 | 0.33 | 3 | 75.0 | 0.270 |
Drug/toxin induced | 3 | 60.0 | 5 | 29.4 | 0.211 | 4 | 80.0 | 12 | 70.6 | 0.678 |
Autoimmune hepatitis | 0 | 0.0 | 3 | 33.3 | - | 0 | 0.0 | 6 | 66.7 | - |
Indeterminate hepatitis | 5 | 18.5 | 2 | 9.5 | 0.381 | 15 | 55.5 | 14 | 66.7 | 0.435 |
Other | 0 | 0.0 | 6 | 50.0 | 0.017 | 5 | 62.5 | 7 | 58.3 | 0.852 |
- Citation: Hey P, Hanrahan TP, Sinclair M, Testro AG, Angus PW, Peterson A, Warrillow S, Bellomo R, Perini MV, Starkey G, Jones RM, Fink M, McClure T, Gow P. Epidemiology and outcomes of acute liver failure in Australia. World J Hepatol 2019; 11(7): 586-595
- URL: https://www.wjgnet.com/1948-5182/full/v11/i7/586.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i7.586